Compiled by the editorial desk with reference to official statements, public filings, and industry data.

DAVOS, Switzerland — A leading psychedelics researcher told a gathering of global elites at the World Economic Forum’s annual meeting that the push to turn substances like MDMA and psilocybin into approved medicines is gaining momentum.

Robin Carhart-Harris, who heads psychedelic research at Imperial College London, said during an interview with Business Insider that “the climate’s looking good” for such treatments. His remarks came after a Wednesday session titled “The New Science of Psychedelics,” which the WEF’s website said explored the “untapped potential” of these drugs.

The discussion arrives amid a broader shift in how policymakers and the public view substances long classified as having no medical value. Psilocybin, the active compound in magic mushrooms, has shown early promise in helping people with anxiety, depression, and alcoholism, according to some studies. Yet researchers caution that the exact effects — and potential side effects — are still under investigation.

Commercial interest is also rising. Some for-profit companies are positioning themselves to sell psychedelic-based therapies, while others offer psilocybin experiences in countries where it is legal, such as the Netherlands. Advocates argue that substances like psilocybin should be reclassified by the U.S. Food and Drug Administration from Schedule 1 — meaning no accepted medical use — to Schedule IV, the category for conventional prescription drugs.

The FDA has approved a limited number of trials involving psilocybin, but the science is still in its infancy. Researchers say more rigorous clinical studies are needed before any widespread medical adoption can occur.

Why the Push Matters

The conversation in Davos reflects a growing acceptance of psychedelics in medical circles, a shift that could have implications for patients and investors alike. If the FDA or other regulators were to reclassify these substances, it could open the door to new treatments for mental health conditions that have proven difficult to manage with existing therapies.

However, the path from research to approval is long and uncertain. The medical community remains divided on how quickly to move, and the influence of private capital — including from Silicon Valley — is a factor that some observers view with caution.

For now, the debate is as much about science as it is about policy and profit. The Davos session, which brought together researchers, business leaders, and policymakers, underscored that psychedelics are no longer a fringe topic but a legitimate subject of mainstream discussion.

As Carhart-Harris’s comments suggest, the climate for psychedelic research may be improving, but the journey from laboratory to pharmacy shelves is far from complete.